Alexandra M. Joyce

I'll research this attorney before drafting.

Let me verify PTAB/IPR activity, bar admissions, and outcomes in key cases.

Alexandra M. Joyce — Patent Litigation Practice Summary

Alexandra M. Joyce is a partner in McCarter & English LLP's Wilmington, Delaware office, where she focuses on intellectual property and complex commercial litigation in the District of Delaware and Delaware state courts. She was elevated to partner effective April 1, 2025, and is ranked in Chambers USA for Intellectual Property (Delaware), currently as "Up and Coming." Her practice spans brand-side pharmaceutical and life-sciences patent litigation — including Hatch-Waxman/ANDA suits and multi-district litigation — as well as patent disputes in biotechnology, medical devices, and technology. She also handles non-patent commercial matters, including trade secret misappropriation, trademark, false advertising, and breach-of-contract claims.

Technology areas and case mix. Her docket is dominated by life sciences and pharmaceutical work (numerous Novartis Hatch-Waxman matters against generic filers including Accord, Mylan, Handa, and HEC Pharm; Eagle Pharmaceuticals' bendamustine litigation; Vanda's tasimelteon cases), with a secondary line of medical-device work (Aerin Medical and Neurent Medical sinus/rhinology disputes) and electronics/software patents (Semisilicon Technology v. inMusic; the Multifold International assertions against Google and Motorola Mobility). She appears most often as Delaware/local counsel (21 of 24 tracked appearances), with a smaller number as lead or counsel of record — consistent with her practice of advising national lead counsel on Delaware procedural and strategic issues.

Side preference. The tracked profile skews plaintiff-side (18 plaintiff vs. 6 defendant), but the plaintiff work is concentrated in brand-pharma Hatch-Waxman enforcement and patent-owner assertions rather than a dedicated NPE/PAE practice. She is comfortable on both sides of the "v." — for example, defending Genzyme against Novartis Gene Therapies and representing defendants in the Unified Patents and Google declaratory-judgment actions involving Multifold — and her role is generally as local counsel rather than as the party's national lead.

Notable matters and outcomes. Her most prominent reported result is ArcherDX (Invitae) v. QIAGEN Sciences, where she was Delaware counsel in a five-day jury trial that returned a 2021 verdict of willful infringement of two ArcherDX/Massachusetts General Hospital DNA-sequencing patents, with roughly $4.7 million in royalties and lost profits; the court entered final judgment in August 2023 (approximately $5.06 million plus an ongoing 7% royalty). That judgment was reversed in its entirety on appeal — the Federal Circuit's September 2025 opinion in Laboratory Corp. of America Holdings v. Qiagen Sciences found non-infringement and directed entry of judgment for Qiagen — so the trial win did not survive appeal. She has also been Delaware counsel in several substantial Hatch-Waxman and IP cases, including the Novartis ANDA litigations, Eagle Pharmaceuticals v. Apotex/Slayback, and Prolitec v. ScentAir (stayed pending inter partes review).

PTAB/IPR experience. Her IPR exposure appears to be primarily in district-court proceedings that run parallel to PTAB challenges — e.g., the Prolitec case was stayed pending IPR, and she is listed as counsel on ArcherDX matters with related PTAB filings — rather than as a frequent first-chair petitioner or patent owner in IPR/PGR proceedings.

Bar/education. She is admitted in Delaware (D. Del. attorney registration No. 6423, documented in court filings). I could not reliably verify her law school or other bar admissions from available sources, so I have omitted them.